Get the Stockscreener App
81.71
1.08%
0.87
Pre-market:
84.11
2.40
+2.94%
Edwards Lifesciences Corp stock is traded at $81.71, with a volume of 4.66M.
It is up +1.08% in the last 24 hours and up +0.09% over the past month.
Spun off from Baxter International in 2000, Edwards Lifesciences designs, manufactures, and markets a range of medical devices and equipment for advanced stages of structural heart disease. It has established itself as a leader across key products, including surgical tissue heart valves, transcatheter aortic valves, and transcatheter mitral and tricuspid valve technologies. The firm derives about 60% of its total sales from outside the US.
See More
Previous Close:
$80.84
Open:
$82.02
24h Volume:
4.66M
Relative Volume:
1.03
Market Cap:
$47.11B
Revenue:
$6.07B
Net Income/Loss:
$1.06B
P/E Ratio:
45.24
EPS:
1.8063
Net Cash Flow:
$1.34B
1W Performance:
+0.55%
1M Performance:
+0.09%
6M Performance:
+7.88%
1Y Performance:
+21.83%
1-Day Range:
$81.36
$82.77
1-Week Range:
$79.40
$82.77
52-Week Range:
$65.94
$87.89
Edwards Lifesciences Corp Stock (EW) Company Profile
Name
Edwards Lifesciences Corp
Sector
Industry
Phone
(949) 250-2500
Address
ONE EDWARDS WAY, IRVINE, CA
Compare EW vs ABT, SYK, MDT, BSX
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
EW
Edwards Lifesciences Corp
|
81.71 | 47.11B | 6.07B | 1.06B | 1.34B | 1.8063 |
ABT
Abbott Laboratories
|
103.56 | 179.95B | 44.33B | 6.50B | 7.40B | 3.717 |
SYK
Stryker Corp
|
340.01 | 130.22B | 25.12B | 3.25B | 4.28B | 8.3984 |
MDT
Medtronic Plc
|
88.65 | 113.82B | 35.48B | 4.64B | 5.41B | 3.582 |
BSX
Boston Scientific Corp
|
62.56 | 92.98B | 20.08B | 2.89B | 3.66B | 1.9391 |
Edwards Lifesciences Corp Stock (EW) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-01-26 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Jan-09-26 | Upgrade | TD Cowen | Hold → Buy |
| Dec-18-25 | Upgrade | JP Morgan | Neutral → Overweight |
| Nov-03-25 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Oct-29-25 | Upgrade | Jefferies | Hold → Buy |
| Oct-29-25 | Upgrade | Wolfe Research | Underperform → Peer Perform |
| Oct-08-25 | Downgrade | Oppenheimer | Outperform → Perform |
| Oct-07-25 | Upgrade | Evercore ISI | In-line → Outperform |
| Jul-29-25 | Upgrade | BTIG Research | Neutral → Buy |
| Apr-24-25 | Upgrade | Piper Sandler | Neutral → Overweight |
| Jan-30-25 | Upgrade | Stifel | Hold → Buy |
| Jan-16-25 | Downgrade | Wolfe Research | Peer Perform → Underperform |
| Dec-16-24 | Upgrade | BofA Securities | Neutral → Buy |
| Oct-11-24 | Resumed | Morgan Stanley | Equal-Weight |
| Sep-18-24 | Downgrade | Jefferies | Buy → Hold |
| Jul-31-24 | Upgrade | Daiwa Securities | Neutral → Outperform |
| Jul-29-24 | Upgrade | Wolfe Research | Underperform → Peer Perform |
| Jul-25-24 | Downgrade | BofA Securities | Buy → Neutral |
| Jul-25-24 | Downgrade | JP Morgan | Overweight → Neutral |
| Jul-25-24 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Jul-25-24 | Downgrade | TD Cowen | Buy → Hold |
| Jul-25-24 | Downgrade | Truist | Buy → Hold |
| May-30-24 | Initiated | Goldman | Buy |
| May-22-24 | Upgrade | Citigroup | Neutral → Buy |
| May-14-24 | Upgrade | Deutsche Bank | Hold → Buy |
| Mar-07-24 | Upgrade | BofA Securities | Neutral → Buy |
| Feb-02-24 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Jan-04-24 | Downgrade | Evercore ISI | Outperform → In-line |
| Dec-11-23 | Downgrade | Citigroup | Buy → Neutral |
| Nov-28-23 | Downgrade | Wolfe Research | Peer Perform → Underperform |
| Sep-26-23 | Upgrade | Oppenheimer | Perform → Outperform |
| Jul-19-23 | Initiated | Robert W. Baird | Outperform |
| May-30-23 | Resumed | Morgan Stanley | Overweight |
| Mar-29-23 | Initiated | UBS | Neutral |
| Mar-08-23 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Feb-06-23 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Jan-31-23 | Downgrade | Bernstein | Outperform → Underperform |
| Jan-30-23 | Downgrade | Piper Sandler | Overweight → Neutral |
| Dec-06-22 | Downgrade | Stifel | Buy → Hold |
| Oct-28-22 | Downgrade | Oppenheimer | Outperform → Perform |
| Oct-26-22 | Initiated | Mizuho | Buy |
| Oct-18-22 | Initiated | Barclays | Overweight |
| Oct-12-22 | Initiated | Jefferies | Buy |
| Jul-29-22 | Downgrade | Canaccord Genuity | Buy → Hold |
| Apr-13-22 | Initiated | Truist | Buy |
| Apr-06-22 | Initiated | Wolfe Research | Outperform |
| Mar-16-22 | Upgrade | Bernstein | Mkt Perform → Outperform |
| Mar-02-22 | Resumed | BofA Securities | Neutral |
| Feb-02-22 | Upgrade | UBS | Neutral → Buy |
| Jan-27-22 | Reiterated | Citigroup | Buy |
| Jan-27-22 | Reiterated | Evercore ISI | Outperform |
| Jan-27-22 | Reiterated | Raymond James | Outperform |
| Jan-27-22 | Reiterated | Stifel | Buy |
| Jan-27-22 | Reiterated | UBS | Neutral |
| Dec-17-21 | Upgrade | JP Morgan | Neutral → Overweight |
| Dec-15-21 | Upgrade | Citigroup | Neutral → Buy |
| Dec-10-21 | Initiated | RBC Capital Mkts | Outperform |
| Dec-06-21 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Jul-30-21 | Reiterated | Canaccord Genuity | Buy |
| Jul-30-21 | Reiterated | Deutsche Bank | Hold |
| Jul-30-21 | Reiterated | Jefferies | Buy |
| Jul-30-21 | Reiterated | Morgan Stanley | Overweight |
| Jul-30-21 | Reiterated | Oppenheimer | Outperform |
| Jul-30-21 | Reiterated | Stifel | Buy |
| Jul-30-21 | Reiterated | UBS | Neutral |
| Jul-30-21 | Reiterated | Wells Fargo | Equal Weight |
| May-25-21 | Initiated | Barclays | Overweight |
| Apr-15-21 | Initiated | Atlantic Equities | Neutral |
| Apr-05-21 | Upgrade | Evercore ISI | In-line → Outperform |
| Dec-16-20 | Downgrade | Citigroup | Buy → Neutral |
| Dec-11-20 | Reiterated | Canaccord Genuity | Buy |
| Sep-11-20 | Initiated | Wolfe Research | Underperform |
| Apr-28-20 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Apr-17-20 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Mar-05-20 | Initiated | Citigroup | Buy |
| Feb-13-20 | Initiated | Goldman | Neutral |
| Feb-06-20 | Resumed | BTIG Research | Neutral |
| Jan-10-20 | Initiated | Oppenheimer | Outperform |
| Jan-02-20 | Downgrade | Evercore ISI | Outperform → In-line |
| Oct-24-19 | Reiterated | Canaccord Genuity | Buy |
| Sep-23-19 | Initiated | Piper Jaffray | Overweight |
| Jul-24-19 | Reiterated | BofA/Merrill | Buy |
| Mar-18-19 | Reiterated | Canaccord Genuity | Buy |
| Jan-18-19 | Upgrade | BofA/Merrill | Neutral → Buy |
| Jan-03-19 | Initiated | Deutsche Bank | Hold |
| Nov-28-18 | Initiated | UBS | Neutral |
| Oct-16-18 | Initiated | Barclays | Underweight |
| Oct-02-18 | Downgrade | BofA/Merrill | Buy → Neutral |
| Oct-02-18 | Downgrade | Guggenheim | Buy → Neutral |
View All
Edwards Lifesciences Corp Stock (EW) Latest News
Edwards Lifesciences Corp. stock rises Wednesday, still underperforms market - MarketWatch
Goldman Sachs Adjusts Price Target on Edwards Lifesciences to $97 From $95, Maintains Buy Rating - marketscreener.com
Sivik Global Healthcare LLC Acquires New Shares in Edwards Lifesciences Corporation $EW - MarketBeat
Rathbones Group PLC Has $1.42 Million Stock Position in Edwards Lifesciences Corporation $EW - MarketBeat
Insider Sell: Daniel Lippis Sells Shares of Edwards Lifesciences Corp (EW) - GuruFocus
Edwards Lifesciences CVP Lippis sells $82,522 in stock - Investing.com
Edwards Lifesciences (EW) CVP exercises options and sells 1,019 shares under 10b5-1 plan - Stock Titan
Edwards Lifesciences (EW) Sees Analyst Rating Maintain with Targ - GuruFocus
Edwards Lifesciences price target lowered to $92 from $94 at Evercore ISI - TipRanks
Nvwm LLC Has $1.46 Million Stock Holdings in Edwards Lifesciences Corporation $EW - MarketBeat
Edwards Lifesciences Corporation (NYSE:EW) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat
Edwards Lifesciences Corporation (EW) Stock Price, News, Quote & History - Yahoo! Finance Canada
Donald Bobo Jr Sells 22,680 Shares of Edwards Lifesciences (NYSE:EW) Stock - marketbeat.com
Edwards Lifesciences (EW) VP sells 22,680 shares after option exercise - Stock Titan
EW Stock Price, Quote & Chart | EDWARDS LIFESCIENCES CORP (NYSE:EW) - ChartMill
Edwards Lifesciences Corp. stock outperforms competitors on strong trading day - MarketWatch
EW Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
EW PE Ratio & Valuation, Is EW Overvalued - intellectia.ai
Edwards Lifesciences Corporation $EW Shares Acquired by J. Safra Sarasin Holding AG - MarketBeat
Assessing Edwards Lifesciences (EW) Valuation As Growth Hopes Contrast With Rich P/E Multiple - finance.yahoo.com
Two Year Data on Edwards Lifesciences’ EVOQUE System Continue to Demonstrate Significant and Sustained Patient Benefits - BioSpace
Edwards Lifesciences Hits Day Low of $78.58 Amid Price Pressure - Markets Mojo
Edwards Lifesciences Corp (EW) Shares Gap Down to $79.34 on Mar 30 - GuruFocus
Edwards Lifesciences Announces New Data on EVOQUE Transcatheter Tricuspid Valve Replacement System - marketscreener.com
Is Edwards Lifesciences (EW) Pricing Look Attractive After Recent Pullback? - simplywall.st
Edwards Lifesciences Corp. stock underperforms Friday when compared to competitors - MarketWatch
What to Expect From Edwards Lifesciences' Next Quarterly Earnings Report - Barchart.com
Vanguard affiliate reports zero holdings in Edwards Lifesciences (NYSE: EW) - Stock Titan
[DEF 14A] Edwards Lifesciences Corp Definitive Proxy Statement - Stock Titan
SG Americas Securities LLC Grows Stock Position in Edwards Lifesciences Corporation $EW - marketbeat.com
Seilern Investment Management Ltd Has $78.71 Million Holdings in Edwards Lifesciences Corporation $EW - MarketBeat
Central Pacific Bank Trust Division Buys New Holdings in Edwards Lifesciences Corporation $EW - Defense World
Is Edwards Lifesciences Corporation (EW) A Good Stock To Buy Now? - Yahoo Finance
Edwards Lifesciences Policy Hire Puts Valuation And Returns In Focus - simplywall.st
AIA Group Ltd Sells 314,688 Shares of Edwards Lifesciences Corporation $EW - MarketBeat
S P Trends: Can Edwards Lifesciences Corporation benefit from deglobalization2026 Recap & Fast Moving Market Watchlists - baoquankhu1.vn
Edwards Lifesciences Corp. stock outperforms competitors despite losses on the day - MarketWatch
Edwards Beats Heart Valve IP Suit Just Before Trial - Law360
Brevan Howard Capital Management LP Has $3.60 Million Stake in Edwards Lifesciences Corporation $EW - MarketBeat
Edwards Lifesciences (EW) Valuation Check After Recent Share Price Momentum - Yahoo Finance
Edwards Lifesciences Stock Hits Day Low of $81.34 Amid Price Pressure - Markets Mojo
Edwards Lifesciences: More Appeal For The Heart (NYSE:EW) - Seeking Alpha
Edwards Lifesciences Corporation $EW Stock Position Lifted by Banco Bilbao Vizcaya Argentaria S.A. - MarketBeat
Edwards Lifesciences Stock (ISIN: US28176E1082) Faces Headwinds Amid Market Cap Dip and Mixed Analys - AD HOC NEWS
EWEdwards Lifesciences Corp Latest Stock News & Market Updates - Stock Titan
Wellington Management Group LLP Buys 977,933 Shares of Edwards Lifesciences Corporation $EW - MarketBeat
Chesapeake Capital Corp IL Makes New $1 Million Investment in Edwards Lifesciences Corporation $EW - MarketBeat
Banque Transatlantique SA Has $2.91 Million Position in Edwards Lifesciences Corporation $EW - MarketBeat
Edwards Lifesciences Hits Day High with Strong 3.21% Intraday Surge - Markets Mojo
Edwards Lifesciences (EW) slips 3.3% as investors digest recent conference remarks and insider-selling filings - Quiver Quantitative
Edwards Lifesciences Corp. Experiences Evaluation Revision Amidst Strong Market Performance - Markets Mojo
Edwards Lifesciences Corp Stock (EW) Financials Data
Revenue
Net Income
Cash Flow
EPS
5.77%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):